

ResistancePlus[®] GC

N. gonorrhoeae + ciprofloxacin susceptibility

Smarter Diagnostics. Simplified Patient Care.



Up to 70% of gonorrhoea infections could be treated with ciprofloxacin, a simple oral antibiotic.¹⁻⁴

- ▶ Guidelines for gonococcal infection (GC) management call to preserve ceftriaxone, recommending ciprofloxacin as an alternative when susceptibility information is available^{5,6}
- ▶ Personalise patient treatment based on antimicrobial resistance (AMR) status
- ▶ Boost utility of your existing GC testing workflows to provide key AMR information

ResistancePlus® GC is a single-well multiplex qPCR test for detection of *Neisseria gonorrhoeae* and *gyrA* markers linked to ciprofloxacin susceptibility.⁷⁻⁹ Dual *N. gonorrhoeae* targets, ciprofloxacin resistance and susceptibility targets offer pathogen detection and AMR determination. **ResistancePlus® GC** is validated for a range of specimen types⁹ and powered by proprietary **PlexPCR®** technologies demonstrating improved multiplex performance compared with other probe-based tests.¹⁰

Single-well **PlexPCR®** test

Channel	Target
1	<i>N. gonorrhoeae</i> (<i>opa</i>)
2	<i>N. gonorrhoeae</i> (<i>porA</i>)
3	<i>gyrA</i> S91F mutation
4	<i>gyrA</i> S91 wild type
5	Internal Control

SpeedX Analysis for **ResistancePlus® GC**

Improve laboratory productivity with a validated software solution for automated result calling and simple data processing. Streamlined workflow to support rapid, routine diagnostics with audit trails and user traceability. Included in contract pricing and installed on a high security and GDPR compliant platform, with LIS compatibility.

Product	Compatible	Size	Cat#
ResistancePlus® GC*	LC480 II	100 reactions	2011001
	ABI 7500/ 7500 Fast / Dx	100 reactions	2013001
	CFX96 Dx / CFX96 Touch	100 reactions	2015001
ResistancePlus® GC Control	All platforms	10 reactions	95003

ResistancePlus® assays are not available in the US. Reach out to learn of options available within the US market.

References: **1.** Gonococcal Isolate Surveillance Project (GISP) Profiles. US Centres for Disease Control and Prevention. Available here: https://www.cdc.gov/sti-statistics/gisp-profiles/index.html#cdc_research_or_data_summary_findings-findings **2.** Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP 2025). UK Health Security Agency" Available here: <https://www.gov.uk/government/publications/gonococcal-resistance-to-antimicrobials-surveillance-programme-grasp-report> **3.** Gonococcal antimicrobial susceptibility surveillance in the EU/ EEA. European Centre for Disease Prevention and Control. Available here: <https://www.ecdc.europa.eu/en/publications-data/gonococcal-antimicrobial-susceptibility-surveillance-eu-eea> **4.** Australian Gonococcal Surveillance Programme (AGSP) 2022 annual report. The Department of Health and Aged Care. Available here: <https://doi.org/10.33321/cdi.2023.47.45> **5.** Gonococcal Infections Among Adolescents and Adults Available here: <https://www.cdc.gov/std/treatment-guidelines/gonorrhea-adults.htm> **6.** Unemo, Magnus, et al. "2020 European guideline for the diagnosis and treatment of gonorrhoea in adults." International journal of STD & AIDS (2020). **7.** Allan-Blitz, Lao-Tzu, et al. "Ciprofloxacin may be efficacious in treating wild-type gyrase A genotype *Neisseria gonorrhoeae* infections." Sexually transmitted diseases 45.4 (2018): e18. **8.** Trembizki, Ella, et al. "Further evidence to support the individualised treatment of gonorrhoea with ciprofloxacin." The Lancet Infectious Diseases 16.9 (2016): 1005-1006. **9.** **ResistancePlus® GC** Instructions for use. **10.** Tan, Lit Yeen, et al. "Superior multiplexing capacity of PlexPrimers enables sensitive and specific detection of SNPs and clustered mutations in qPCR." PLoS One 12.1 (2017): e0170087.

ResistancePlus® GC kits are developed and manufactured by **SpeedX Pty Ltd**, Sydney. **PlexPCR®** & **ResistancePlus®** are trademarks of **SpeedX Pty Ltd**. Other copyright and trademarks are the property of the respective owners. **SpeedX Pty Ltd** products may be covered by one or more local or foreign patents. Visit www.speedxpcr.com/patents for comprehensive patent information.

Demonstrated clinical performance⁹

	GC Detection	<i>gyrA</i> Detection
Sensitivity	100%	100%
Specificity	99.2%	100%

Validated for urine, swabs (anal, rectal, vaginal, and pharyngeal) and extracts.⁹

- ▶ Dual target, single-well test solution, suitable for confirming GC positives or for upfront testing with simultaneous resistance status
- ▶ Help preserve last-line antibiotics when identifying ciprofloxacin as an alternative treatment pathway
- ▶ Easily obtain ciprofloxacin susceptibility data on a range of specimen types

Australia - SpeedX Pty. Ltd.

+61 (0)2 9209 4170

sales@speedx.com.au

Europe - SpeedX Ltd.

+44 (0)330 445 0036

sales.uk@speedx.com.au

Find out more **speedxpcr.com**

